In short
This article discusses the clinical trials of GAd20-209-FSP, an innovative genetic vaccine being studied for the treatment of microsatellite unstable solid tumors, particularly in patients with advanced colorectal cancer. The trials aim to assess the safety, tolerability, and effectiveness of this vaccine when used in combination with pembrolizumab, an immunotherapy drug.
At a glance
- Study Type
- Phase I/II, Multi-center, Open-Label Study
- Investigational Drug
- GAd20-209-FSP (Nous-209) Genetic Vaccine
- Target Condition
- Microsatellite Unstable Solid Tumors, specifically MSI-H or dMMR Colorectal Cancer
- Combination Therapy
- GAd20-209-FSP + Pembrolizumab
- Primary Endpoint
- Overall Response Rate (ORR) assessed by RECIST v1.1 criteria
- Key Secondary Endpoints
- Safety, tolerability, Best Overall Response, Duration of Response, Progression-Free Survival
- Administration Route
- Intramuscular injection
- Key Eligibility Criteria
- Age ≥18 years, confirmed MSI-H or dMMR status, adequate organ function, ECOG performance status 0/1
What is GAD20-209-FSP-A4?
GAD20-209-FSP-A4 is part of a genetic vaccine called Nous-209, which is being studied for the treatment of certain types of cancer. This vaccine is considered an advanced therapy, specifically a gene therapy product. It's important to note that GAD20-209-FSP-A4 is one of four components that make up the complete Nous-209 vaccine.
How Does It Work?
The Nous-209 vaccine, which includes GAD20-209-FSP-A4, works in a unique way: It's based on a virus called adenovirus, specifically one found in great apes (GAd20). The vaccine carries genetic material that encodes for 209 Frame Shift Peptides (FSPs). These are special proteins that are often found in certain types of cancer cells. When introduced into the body, it's designed to stimulate the immune system to recognize and attack cancer cells that have these specific proteins. This approach is a form of immunotherapy, which means it uses the body's own immune system to fight cancer.
Target Conditions
The Nous-209 vaccine, including GAD20-209-FSP-A4, is being studied for the treatment of: Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that is locally advanced and can't be surgically removed, or has spread to other parts of the body (metastatic). These terms (MSI-H and dMMR) refer to specific genetic characteristics of the cancer that make it potentially responsive to this type of treatment.
Clinical Trial Information
The vaccine is currently being studied in a clinical trial: It's a Phase I/II trial, which means it's testing both the safety and how well the treatment works. The trial is testing the vaccine in combination with another drug called pembrolizumab, which is also an immunotherapy. The main goal is to see how many patients respond to the treatment (called the Overall Response Rate or ORR). The trial is also looking at how safe the treatment is and how long the responses last.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key points include: Be 18 years or older. Have confirmed MSI-H or dMMR colorectal cancer. Have cancer that can't be surgically removed or has spread. Have a life expectancy of at least 6 months. Have good overall health and organ function. There are also several conditions that would prevent a person from participating, such as certain other medical conditions or previous treatments.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks: Potential benefits: The treatment might help slow down or stop the growth of cancer, or even shrink tumors in some patients. Potential risks: The treatment might cause side effects. The trial is carefully monitoring for any adverse events. It's important to note that as this is an experimental treatment, not all potential risks are known, and the benefits are not guaranteed.